Nature Communications (Mar 2019)
Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma
- Jong-Sung Park,
- Yumin Oh,
- Yong Joo Park,
- Ogyi Park,
- Hoseong Yang,
- Stephanie Slania,
- Laura K. Hummers,
- Ami A. Shah,
- Hyoung-Tae An,
- Jiyeon Jang,
- Maureen R. Horton,
- Joseph Shin,
- Harry C. Dietz,
- Eric Song,
- Dong Hee Na,
- Eun Ji Park,
- Kwangmeyung Kim,
- Kang Choon Lee,
- Viktor V. Roschke,
- Justin Hanes,
- Martin G. Pomper,
- Seulki Lee
Affiliations
- Jong-Sung Park
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Yumin Oh
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Yong Joo Park
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Ogyi Park
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Hoseong Yang
- Department of Dermatology, Johns Hopkins University School of Medicine
- Stephanie Slania
- Department of Biomedical Engineering, Johns Hopkins University School of Medicine
- Laura K. Hummers
- Scleroderma Center, Division of Rheumatology, Johns Hopkins University School of Medicine
- Ami A. Shah
- Scleroderma Center, Division of Rheumatology, Johns Hopkins University School of Medicine
- Hyoung-Tae An
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Jiyeon Jang
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Maureen R. Horton
- Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine
- Joseph Shin
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine
- Harry C. Dietz
- McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine
- Eric Song
- Department of Immunobiology, Yale University School of Medicine
- Dong Hee Na
- College of Pharmacy, Chung-Ang University
- Eun Ji Park
- College of Pharmacy, Chung-Ang University
- Kwangmeyung Kim
- Biomedical Research Institute, Korea Institute of Science and Technology
- Kang Choon Lee
- School of Pharmacy, SungKyunKwan University
- Viktor V. Roschke
- Theraly Fibrosis Inc.
- Justin Hanes
- Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine
- Martin G. Pomper
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- Seulki Lee
- Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-019-09101-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 11
Abstract
Dermal myofibroblasts are responsible for fibrosis development in scleroderma. Here the authors show that a bioengineered recombinant human TRAIL ligand reverses established fibrosis in mouse models of scleroderma by targeting the death receptor 5 and inducing apoptosis of myofibroblasts.
